Cancer, MET, and EXON 14

What is MET, c-Met, or EXON 14?

c-Met is a protein in the body, transcribed by the MET gene, that plays a role in cell growth. Sometimes, c-Met is altered, meaning it doesn’t look or work the way it’s supposed to.

Amplifications, fusions, and EXON 14 skipping mutations are all types of c-Met alterations or gene dysregulations. Research suggests that EXON 14 skipping mutations are more often found in patients with lung cancer than other types of cancer.

What is the relationship between MET and cancer?

Cancer harms the body when altered cells divide uncontrollably to form lumps or masses of tissue called tumors. c-Met is a protein that is frequently affected, or altered, in cancers. These alterations can be at the protein level or MET gene level (amplification or fusion). Cancer cells sometimes have an altered c-Met protein. An altered c-Met protein or MET gene may cause tumors to grow rapidly and become untreatable by certain cancer therapies.

Therefore, the c-Met pathway is considered an important target for cancer therapies. The SPARTA study is exploring a potential cancer therapy that targets altered c-Met and MET gene (such as amplifications, fusions, and EXON 14 skipping mutations).

Why should you get tested for EXON 14 or other c-Met alterations?

Getting tested for a c-Met alteration gives you more information about your cancer and helps you make better decisions about your care.

If you know that you have an alteration in c-Met, find out if the SPARTA study drug is right for you.

Study Drug
Copyright © 2020   |  SPARTA Study  |   All Rights Reserved   |  Privacy    |  Terms & Conditions